Amgen, Inc. vs Quantumscape Corp — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Quantumscape Corp trades at $6.38 (market cap $3.90B). The key difference: Amgen, Inc. is far larger — about 57.5× Quantumscape Corp's market cap, and Amgen, Inc. pays a 2.43% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| AMGN | QS | |
|---|---|---|
Market Cap | $224.14B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $18.44 |
52-Week Low | $271.18 | $4.89 |
Enterprise Value | $267.45B | $3.11B |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →